Vitamin C (Acidum Ascordicum; pharmacopoeial synonym Acidum ascorbicum) Veterinary Grade API is an uncoated free-acid starting material intended for incorporation into tablets, injections, capsules, powders, granules, premixes, and drinking-water solutions. The substance is L-ascorbic acid, CAS 50-81-7, molecular formula C₆H₈O₆, molar mass 176.12 g/mol, with pK_a1 4.17 and pK_a2 11.6 at 25 °C. The material is recognised under the current Ascorbic Acid monograph of the European Pharmacopoeia (Ph. Eur. 0253) and the corresponding USP Ascorbic Acid monograph. It is supplied as a white or almost white crystalline powder or colourless crystals, freely soluble in water, sparingly soluble in ethanol, and practically insoluble in chlorinated solvents. No universal model code exists across manufacturers; typical commercial designations differentiate crystalline, fine-powder, direct-compression, and premix qualities by sieve fraction, bulk density, and particle-size distribution. The API is not a finished dosage form and is administered only after formulation, target-species stability testing, and marketing authorisation.

Because ascorbic acid is a reducing agent with sensitivity to oxidative degradation in the presence of free transition-metal ions, powder handling and formulation equipment require defined product-contact materials. Stainless steel 316L product-contact surfaces, nitrogen blanketing of storage hoppers, and processing-suite relative humidity below 40–50% RH are standard controls in veterinary API repackaging and solid-dose manufacturing. Copper(II) and iron(III) ions accelerate degradation in aqueous solution; chelation, purified water quality, and removal of free metal ion contamination are necessary before dissolution. Milling and sieving should employ low-shear equipment because high-energy impact mills can generate localised hot spots that darken the powder. The degradation risk changes with water activity, heat history, headspace oxygen, and the presence of mineral premix components.

Compendial identity, purity, and assay profile

The specification profile below summarises core release criteria for the veterinary API when tested against current pharmacopoeial methods. Acceptance values are drawn from public monograph limits and should be verified against the current edition cited in the dossier.

Release testing also includes residual solvent determination where solvent crystallisation is used; published data for this specific veterinary configuration is limited where the dossier does not state a solvated crystallisation path. The melting range is reported as 190–192 °C with decomposition and is used as an identity criterion rather than a stability indicator. Particle-size distribution is determined by laser diffraction according to ISO 13320 or by the current pharmacopoeial sieve method when a grade-specific particle-size claim is assigned.

How Does the Uncoated Free Acid Differ from Buffered or Esterified Derivatives?

The uncoated free acid differs from sodium ascorbate, calcium ascorbate, ascorbyl palmitate, and ascorbyl 2-phosphate in pH, hygroscopicity, oxidative stability, and compatibility with mineral-fortified premixes. Sodium ascorbate yields a less acidic solution pH and is selected when drinking-water preparations must avoid pH depression in distribution lines; it is more hygroscopic as a dry powder and requires moisture-controlled packaging. Calcium ascorbate supplies calcium but reduces ascorbic acid content per gram compared with the free acid, which is relevant in dose calculations for poultry, swine, and bovine formulations. Ascorbyl palmitate is lipophilic and is not a first-choice source for aqueous veterinary formulations. Ascorbyl 2-phosphate is more stable in the presence of divalent metal ions and is used in mineral-vitamin premixes where free ascorbic acid would degrade rapidly; it is not a direct substitute when the marketing authorisation specifies the compendial free-acid entity. Compared with food- or feed-grade material, the veterinary API is not automatically lower in chemical purity; the distinction lies in documented GMP compliance under ICH Q7, veterinary-specific certificate of analysis, and suitability for sterile and non-sterile veterinary medicinal products. Feed-grade ascorbic acid may not meet bacterial endotoxin, related-substance, and particulate-matter requirements needed for injection-grade formulation.

In direct-compression tablet applications, the API is normally blended with microcrystalline cellulose, lactose monohydrate, and a glidant at 0.5–2.0% of the tablet mass. A rotary tablet press with force feeder is preferred because ascorbic acid powders containing a significant fraction below 75 µm can segregate and adhere to punch faces. Production-scale rooms are maintained below 35–45% RH, and residual moisture in the final blend above 0.5% increases picking and sticking. A direct-compression grade is selected with median particle size near 150–250 µm, tapped density above 0.7 g/cm³, and not more than 20% passing a 75 µm sieve. Wet granulation is used when the API is poorly compressible in a given formula; the binder is added in an aqueous or hydroalcoholic solution and dried in a fluid-bed dryer at inlet air temperature not exceeding 50–60 °C to limit degradation. Dry granulation by roller compaction is used for moisture-sensitive formulations. Tablets are evaluated under USP general chapters 905 Uniformity of Dosage Units, 701 Disintegration, and 711 Dissolution when a finished-product monograph exists.

Aqueous injectable solutions containing the free acid are prepared by dissolving the API in Water for Injections and adjusting pH with sodium bicarbonate or sodium hydroxide to the finished-product monograph target. Unbuffered ascorbic acid solutions are too acidic for parenteral administration. Pharmaceutical-grade nitrogen sparging is used to reduce dissolved oxygen below 0.5 mg/L; filling is performed under aseptic conditions using 316L stainless steel or glass-lined storage. Heat sterilisation at 121 °C for 15 minutes is limited by degradation and discoloration, so sterile filtration through 0.22 µm membrane filters is used when the formulation is heat-labile. Typical monograph limits for Ascorbic Acid Injection USP cite pH 5.5–7.0. The finished injection is protected from light and headspace oxygen in amber glass or oxygen-barrier polymer ampoules; published data for this specific configuration is limited where the packaging and antioxidant package have not been fully validated.

The dosage-form-specific risk profile and the corresponding control approach are summarised below.

When Premix Homogeneity Depends on Geometric Dilution and Particle-Size Overlap

Premix and granule production requires geometric dilution when the active inclusion rate is below 1–5 kg per tonne. A 1% active premix is prepared by mixing 1 part ascorbic acid with 9 parts carrier in a first step, then diluting the 10-part mixture with 90 parts carrier in a second step. The carrier is usually dextrose monohydrate, lactose, or ground maize cobs chosen to match the particle-size distribution of the API; particle-size overlap between API and carrier reduces segregation during transfer. Mixing is conducted in a double-ribbon mixer or paddle mixer at 20–30 rpm until the homogeneity validation study reaches a coefficient of variation ≤ 5% for assayed samples taken from at least 10 stratified positions. Assay of ascorbic acid in premix samples is performed by HPLC-UV at 245 nm or by iodometric titration after extraction in metaphosphoric acid solution. Premixes intended for drinking water must dissolve without foaming; solubility above 20 °C is not limiting, but hard water alkalinity may raise solution pH and shorten stability after dilution.

Stability-Limiting Interactions with Trace Minerals, Moisture, and Oxidising Agents in Medicated Feed

Dry ascorbic acid is relatively stable at low humidity and in the absence of metal catalysts. In vitamin-mineral premixes, free copper(II), iron(II/III), zinc(II), and manganese(II) shorten ascorbic acid retention; the most damaging contact is with copper sulfate pentahydrate and ferrous sulfate heptahydrate. When the formulation requires simultaneous mineral and vitamin C addition, the mineral source should be chelated, coated, or packed in a separate compartment. Moisture ingress above 60% RH in gas-permeable bags triggers surface dissolution and browning; aluminium-foil-lined bags with heat-sealed closures are recommended for bulk storage. Ascorbic acid should not be dry-blended with alkaline salts such as sodium bicarbonate where residual moisture can initiate an acid-base reaction. Storage follows the pharmacopoeial instruction: tightly closed, non-metallic containers, protected from light and heat. Tropical stability studies at 40 °C/75% RH are used to justify shelf-life for regulatory submissions. Browning is a visible marker for degradation, but assay loss may precede visible change.

Analytical method transfer into the veterinary manufacturing site should include verification of assay, related substances, and pH against the current Ph. Eur. Ascorbic Acid monograph 0253 or the corresponding USP monograph. HPLC-UV at 245 nm is preferred over titration when coloured feed matrices are present. The limit of quantification should be established for each finished matrix; metaphosphoric acid extraction stabilises ascorbic acid during sample preparation. For solid dosage forms, process validation is normally carried out on at least three consecutive pilot-scale lots with testing for blend uniformity, content uniformity, dissolution, and moisture. In drinking-water solutions, the prepared solution should be used within the completion time established by the stability study; published data for this specific configuration is limited if water quality, pipe material, and temperature profile have not been disclosed. Lot-to-lot variability of the veterinary-grade API is controlled by the manufacturer’s quality system under ICH Q7 and EudraLex Volume 4 Part II, with a certificate of analysis for each delivery lot.